Literature DB >> 21591761

Identification of RNA pseudoknot-binding ligand that inhibits the -1 ribosomal frameshifting of SARS-coronavirus by structure-based virtual screening.

So-Jung Park1, Yang-Gyun Kim, Hyun-Ju Park.   

Abstract

Programmed -1 ribosomal frameshifting (-1 RF) is an essential regulating mechanism of translation used by SARS-CoV (severe acute respiratory syndrome coronavirus) to synthesize the key replicative proteins encoded by two overlapping open reading frames. The integrity of RNA pseudoknot stability and structure in the -1 RF site is important for efficient -1 RF. Thus, small molecules interacting with high affinity and selectivity with the RNA pseudoknot in the -1 RF site of SARS-CoV (SARS-pseudoknot) would disrupt -1 RF and be fatal to viral infectivity and production. To discover ligands for the SARS-pseudoknot by virtual screening, we constructed a 3D structural model of the SARS-pseudoknot and conducted a computational screening of the chemical database. After virtual screening of about 80,000 compounds against the SARS-pseudoknot structure, high-ranked compounds were selected and their activities were examined by in vitro and cell-based -1 RF assay. We successfully identified a novel ligand 43 that dramatically inhibits the -1 RF of SARS-CoV. This antiframeshift agent is an interesting lead for the design of novel antiviral agents against SARS-CoV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21591761     DOI: 10.1021/ja1098325

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  51 in total

1.  Programmed -1 frameshifting efficiency correlates with RNA pseudoknot conformational plasticity, not resistance to mechanical unfolding.

Authors:  Dustin B Ritchie; Daniel A N Foster; Michael T Woodside
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

Review 2.  Ribosomal frameshifting and transcriptional slippage: From genetic steganography and cryptography to adventitious use.

Authors:  John F Atkins; Gary Loughran; Pramod R Bhatt; Andrew E Firth; Pavel V Baranov
Journal:  Nucleic Acids Res       Date:  2016-07-19       Impact factor: 16.971

Review 3.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

Review 4.  Synthetic small-molecule RNA ligands: future prospects as therapeutic agents.

Authors:  A Di Giorgio; M Duca
Journal:  Medchemcomm       Date:  2019-04-30       Impact factor: 3.597

Review 5.  Physical and Functional Analysis of Viral RNA Genomes by SHAPE.

Authors:  Mark A Boerneke; Jeffrey E Ehrhardt; Kevin M Weeks
Journal:  Annu Rev Virol       Date:  2019-07-23       Impact factor: 10.431

6.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

7.  Small synthetic molecule-stabilized RNA pseudoknot as an activator for -1 ribosomal frameshifting.

Authors:  Saki Matsumoto; Neva Caliskan; Marina V Rodnina; Asako Murata; Kazuhiko Nakatani
Journal:  Nucleic Acids Res       Date:  2018-09-19       Impact factor: 16.971

Review 8.  Small molecule targeting of biologically relevant RNA tertiary and quaternary structures.

Authors:  Martina Zafferani; Amanda E Hargrove
Journal:  Cell Chem Biol       Date:  2021-04-05       Impact factor: 8.116

Review 9.  Unconventional viral gene expression mechanisms as therapeutic targets.

Authors:  Jessica Sook Yuin Ho; Zeyu Zhu; Ivan Marazzi
Journal:  Nature       Date:  2021-05-19       Impact factor: 49.962

10.  Modulation of ribosomal frameshifting frequency and its effect on the replication of Rous sarcoma virus.

Authors:  Emily I C Nikolic; Louise M King; Marijana Vidakovic; Nerea Irigoyen; Ian Brierley
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.